Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($0.60), $0.15 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $27.4 million versus the consensus estimate of $47.81 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.